Cargando…
New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that combines an antigen-specific antibody backbone bound...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400777/ https://www.ncbi.nlm.nih.gov/pubmed/36046357 http://dx.doi.org/10.37349/etat.2022.00069 |
_version_ | 1784772816389799936 |
---|---|
author | Koster, Kira-Lee Huober, Jens Joerger, Markus |
author_facet | Koster, Kira-Lee Huober, Jens Joerger, Markus |
author_sort | Koster, Kira-Lee |
collection | PubMed |
description | Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that combines an antigen-specific antibody backbone bound to a potent cytotoxic agent (the payload), via a linker, contributing to an improved therapeutic index. Currently, three ADCs received approval by the US Food and Drug Administration (FDA) and are in routine clinical use in different treatment settings; many more ADCs are in earlier and later stages of development, and their future approval will improve treatment options for patients with advanced but potentially also early-stage BC over time. Just recently, the results of three phase 3 trials (ASCENT, TULIP, and DESTINY-Breast03) evaluating sacituzumab govitecan (SG), trastuzumab duocarmazine, and trastuzumab deruxtecan (T-DXd) in different treatment settings were presented and showed promising results. This overview focuses on the newer ADCs, including T-DXd and SG, their pharmacology, mechanisms of action, and relevant studies. In addition, the latest results from trials investigating some newer ADCs, in further stages of development are presented. |
format | Online Article Text |
id | pubmed-9400777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Open Exploration |
record_format | MEDLINE/PubMed |
spelling | pubmed-94007772022-08-30 New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development Koster, Kira-Lee Huober, Jens Joerger, Markus Explor Target Antitumor Ther Review Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that combines an antigen-specific antibody backbone bound to a potent cytotoxic agent (the payload), via a linker, contributing to an improved therapeutic index. Currently, three ADCs received approval by the US Food and Drug Administration (FDA) and are in routine clinical use in different treatment settings; many more ADCs are in earlier and later stages of development, and their future approval will improve treatment options for patients with advanced but potentially also early-stage BC over time. Just recently, the results of three phase 3 trials (ASCENT, TULIP, and DESTINY-Breast03) evaluating sacituzumab govitecan (SG), trastuzumab duocarmazine, and trastuzumab deruxtecan (T-DXd) in different treatment settings were presented and showed promising results. This overview focuses on the newer ADCs, including T-DXd and SG, their pharmacology, mechanisms of action, and relevant studies. In addition, the latest results from trials investigating some newer ADCs, in further stages of development are presented. Open Exploration 2022 2022-02-24 /pmc/articles/PMC9400777/ /pubmed/36046357 http://dx.doi.org/10.37349/etat.2022.00069 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Koster, Kira-Lee Huober, Jens Joerger, Markus New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development |
title | New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development |
title_full | New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development |
title_fullStr | New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development |
title_full_unstemmed | New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development |
title_short | New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development |
title_sort | new antibody-drug conjugates (adcs) in breast cancer—an overview of adcs recently approved and in later stages of development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400777/ https://www.ncbi.nlm.nih.gov/pubmed/36046357 http://dx.doi.org/10.37349/etat.2022.00069 |
work_keys_str_mv | AT kosterkiralee newantibodydrugconjugatesadcsinbreastcanceranoverviewofadcsrecentlyapprovedandinlaterstagesofdevelopment AT huoberjens newantibodydrugconjugatesadcsinbreastcanceranoverviewofadcsrecentlyapprovedandinlaterstagesofdevelopment AT joergermarkus newantibodydrugconjugatesadcsinbreastcanceranoverviewofadcsrecentlyapprovedandinlaterstagesofdevelopment |